The short version of visceral adiposity fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-21 and is reviewed periodically as new material appears.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility | Soluble in water | Consistent with peptide nature |
| Typical storage | 2 to 8 degrees Celsius | Refrigerated, dry, protected from light |
| Common analytical method | Reversed-phase HPLC | Purity and impurity profiling |
| Identity confirmation | Mass spectrometry | Molecular mass verification |
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
=== Preparation === This compound is prepared by oxidation of 4-aminodimethylaniline in the presence of sodium thiosulfate to give the quinonediiminothiosulfonic acid, reaction with dimethylaniline, oxidation to the indamine, and cyclization to give the thiazine:
The Transitional Federal Government sought to reestablish its authority, and, with the assistance of Ethiopian troops, African Union peacekeepers and air support by the United States, drove out the ICU and solidified its rule. On 8 January 2007, TFG President Abdullahi Yusuf Ahmed entered Mogadishu with the Ethiopian military support for the first time since being elected to office. The government then relocated to Villa Somalia in the capital from its interim location in Baidoa. This marked the first time since the fall of the Siad Barre regime in 1991 that the federal government controlled most of the country.
In some parts of Europe and India, Datura has been a popular poison for suicide and murder. From 1950 to 1965, the State Chemical Laboratories in Agra, India, investigated 2,778 deaths caused by ingesting Datura. A group called Thugs (practicers of thuggee) were reportedly devotees of an Indian religious cult made up of robbers and assassins who strangled or poisoned their victims in rituals devoted to the Hindu goddess Kali. They were alleged to employ Datura in many such poisonings, using it also to induce drowsiness or stupefaction, making strangulation easier. Datura toxins may be ingested accidentally by consumption of honey produced by several wasp species, including Brachygastra lecheguana, during the Datura blooming season. These semi-domesticated honey wasps apparently collect Datura nectar for honey production, which can lead to poisoning. The U.S. Centers for Disease Control and Prevention reported accidental poisoning resulting in hospitalization for a family of six who inadvertently ingested Datura used as an ingredient in stew. In some places around the world, such as India due to the Drug & Cosmetic Act 1940 & Rule 1995, buying, selling, or cultivating Datura plants is prohibited. Solanaceous tribes with a similar chemistry (i.e.
Small bowel/intestinal dialysis puts the dialysate in the small intestines through a surgical opening (ileostomy), using the intestinal walls as the semipermeable membrane for removing toxins. It did not show any actual survival benefit overall and was replaced by modern dialysis methods. Induced diarrhea has been found to provide toxin removal in small, non-randomly controlled studies. One method uses the ingestion of 1 to 1.5 liters of non-absorbable solutions of polyethylene glycol or mannitol every fourth hour. Colonic dialysis puts the dialysate in the colon, which can be done without a surgical opening: an anal catheter inserted through the anus can reach the ascending colon and inject the dialysate there. The clinical use of colonic dialysis is still in its early stages (as of 2020), being studied mainly in Iran and China. Oral adsorbents are used in hope that they will absorb toxins as they pass through the gut. One of them, AST-120, has undergone two multinational randomized controlled trials in which it failed to show a benefit in slowing CKD progression. However, a post-hoc analysis finds some benefit in a subgroup of patients. A related development is supplementation with soluble fibres such as acacia fibre into the diet. These fibers are digested by bacteria in the colon. This bacterial growth increases the amount of nitrogen that is eliminated in fecal waste.
Sources: en.wikipedia.org
=== Historical === In 1888, the French botanist Gaston Bonnier demonstrated early experimental evidence for lichen symbiosis through his work with X. parietina (then called Parmelia parietina). He reported creating artificial lichen thalli by replacing the organism's natural algal partner (Protococcus viridis) with different algae species, including Protococcus botryoides and the filamentous reddish alga Trentepohlia abietina. While his methods foreshadowed modern microbiological techniques and represented a significant step for the time, modern assessments note critical limitations. His algal sources were not truly isolated (coming from other lichen thalli), and his "synthesized lichens" only vaguely resembled natural specimens, showing fungal hyphae surrounding algal cells but lacking true lichen morphology. In 1967, Richardson conducted early transplant experiments with X. parietina that helped establish methods for studying lichen adaptability. Using a novel technique of attaching lichen thalli to new substrates with resin glue, the study achieved a 96% survival rate in transplanted specimens. When coastal specimens (var. ectanea) were moved to farm roofs in Oxford, they showed significant morphological changes within 18 months, including increased lobe width from 0.8 mm to 2.4 mm. The study also demonstrated that parietin production could adapt to local conditions within six months, with transplanted specimens eventually matching the pigment levels of native populations.
==== Absorption ==== Pseudoephedrine is orally active and is readily absorbed from the gastrointestinal tract. Its oral bioavailability is approximately 100%. The drug reaches peak concentrations after 1 to 4 hours (mean 1.9 hours) in the case of the immediate-release formulation and after 2 to 6 hours in the case of the extended-release formulation. The onset of action of pseudoephedrine is 30 minutes.
Antibody Solutions is a privately held American contract research organization headquartered in Santa Clara, California. It provides research and discovery services and fit-for-purpose antibodies to biopharmaceutical and diagnostic companies and academic researchers worldwide. The company’s services include monoclonal and polyclonal antibody and antigen development, molecular modeling, antibody sequencing and engineering, bioreactor technology, pharmacokinetic studies, antibody epitope binning, peptide synthesis, immunoassay development, ligand-binding assay analysis, and support for CAR-T research.
Sources: en.wikipedia.org
In ruling on the 1986 Huanchaca case involving the slaying of a leading Bolivian scientist, his pilot, and a guide, the Third Criminal Court of Santa Cruz returned a guilty verdict in April 1988 against ten Brazilians and a Colombian, in addition to a Bolivian thought to be dead. The court, however, dismissed charges against five other Bolivian suspects, including several well-known drug traffickers. The freeing of two of the suspects by the Santa Cruz judges prompted the Supreme Court of Justice to demand the resignations of the entire Santa Cruz judiciary because of its leniency toward drug traffickers. Four Santa Cruz judges were dismissed because of irregularities in the Huanchaca case, which in early 1989 remained at an impasse, under advisement in the Supreme Court of Justice. Drug kingpin Roberto Suárez Gómez was arrested in 1988. Under the 1988 Antinarcotics Law, the Judicial Police must report antinarcotics operations to the closest Special Antinarcotics Force district within forty-eight hours. The law also called for the creation of three-judge Special NarcoticsControl Courts or tribunals (Juzgados Especiales de Narcotráfico) with broad responsibilities. In early 1989, the Supreme Court of Justice began appointing judges and lawyers to serve on the new tribunals, two of which began functioning as tribunals of first instance in narcotics-related cases, with jurisdiction for the judicial districts of La Paz, Cochabamba, Santa Cruz, and Beni.
=== Notable alumni and faculty === John Shaw Billings - began process to organize world's medical literature, now PubMed Gerald Buckberg - an American physician whose research interests centered in the area of myocardial protection and led to the introduction of blood cardioplegia Tommy Casanova - American physician, football player and politician M. H. Cleary - American lawyer, physician and activist Robin T. Cotton - English physician who is well known for his work in pediatric otolaryngology William W. Ellsberry - U.S. Representative from Ohio Thomas J. Fogarty - an American surgeon and medical device inventor best known for the invention of the embolectomy catheter, or balloon catheter Alonzo Garcelon - the 36th Governor of Maine, and a surgeon general of Maine during the American Civil War Marilyn Gaston - expert on sickle-cell disease Bertha Lund Glaeser (1862–1939) – American physician Jack Horsley - American former competition swimmer and Olympic medalist Frank F. Ledford Jr. an American orthopedic surgeon who served as the 37th Surgeon General of the United States Army Jeanne Lusher - an American physician, pediatric hematologist/oncologist, and a researcher in the field of bleeding disorders of childhood Anna Ornstein - Auschwitz survivor, psychoanalyst and psychiatrist, author, speaker, and scholar Scott L. Pomeroy - the Bronson Crothers Professor of Neurology and Director of the Intellectual and Developmental Disabilities Research Center of Harvard Medical School James B.
== Veterinary use == There is limited data on nalbuphine's use in the dog, and even less for that of other animals. Nalbuphine induces sedation and analgesia in the dog but is less effective compared to μ-opioid receptor agonists. Nalbuphine has minimal effect on the cardiovascular system. The sedation provided by nalbuphine is insufficient for catheterisation and fur clipping and the analgesic effect is insufficient for some pain. Both sedative and analgesic effects of nalbuphine are subject to a ceiling effect. Combination of nalbuphine with an α2-adrenergic receptor agonist or acepromazine provides greater sedation. One study found that acepromazine and nalbuphine failed to provide adequate analgesia both during and post-surgery in bitches undergoing ovariohysterectomy. Although one study found epidural nalbuphine to provide adequate analgesia there is limited evidence to support epidural administration of nalbuphine. Ophthalmic administration is not recommended in any species as multiple studies demonstrated no analgesia following topical ophthalmic administration. In cats nalbuphine has been shown to provide an equal sedative effect to butorphanol when adminsistered with acepromazine and an equal sedative and analgesic effect when combined with dexmedetomidine and tiletamine-zolazepam respectively. In horses evidence is mixed. One study found that nalbuphine combined with xylazine was more effective than xylazine by itself as an analgesic and anaesthetic, but another study found no difference between xylazine itself and xylazine with nalbuphine.
Sources: en.wikipedia.org
Refrigeration between 2 and 8 degrees Celsius is typical, with protection from moisture and light. Dry, sealed containers help maintain stability over the labeled shelf life. Temperature cycling is usually minimized.
Reversed-phase high-performance liquid chromatography is commonly used to separate and quantify the peptide and its impurities. Mass spectrometry is often paired with it to confirm identity. Together they provide a profile of related substances.
Extreme pH values accelerate hydrolytic degradation of the peptide backbone. Buffered solutions in a near-neutral range generally slow this process. Solution age and temperature also affect the rate of breakdown.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.